{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:48:33Z","timestamp":1773254913429,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Catheter locking solutions\u2014including trisodium citrate\u2014are crucial for maintaining central venous catheter patency in end\u2010stage renal disease patients. Despite widespread usage, discrepancies remain regarding the safety profile of trisodium citrate. This study evaluates the safety of 30% trisodium citrate relative to alternative solutions in a large, heterogenous population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 83,306 catheters from 51,243 patients at Fresenius Medical Care clinics across Europe, the Middle East, Africa, and Latin America from October 15, 2011 to 31 August 31, 2021. The 30% trisodium citrate group (10,689 patients) comprised all catheters routinely locked with 30% trisodium citrate. The control group (40,554 patients) included catheters locked with various non\u2010trisodium citrate solutions, most commonly heparin, along with saline, gentamicin, and, less frequently, alteplase, antimicrobial caps (isopropyl alcohol or chlorhexidine), or taurolidine. Mean follow\u2010up was 116\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Chi\u2010square testing identified significant differences in three of four adverse event categories between the 30% trisodium citrate and control groups. The 30% trisodium citrate showed a favorable risk profile for Catheter and Procedure Issues (RR\u2009=\u20090.27, 95% CI: 0.25\u20130.28), Systemic Reactions and Symptoms (RR\u2009=\u20090.10, 95% CI: 0.09\u20130.11), and Thrombotic or Coagulation Complications (RR\u2009=\u20090.60, 95% CI: 0.58\u20130.61). No significant difference emerged for Infection\u2010Related Events (RR\u2009=\u20091.02, 95% CI: 0.98\u20131.07).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These results support the relative safety of 30% trisodium citrate as a locking solution in a large, diverse patient cohort. Further research should further explore how patient\u2010level, catheter\u2010level, and facility\u2010level factors influence the comparative safety of locking solutions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hdi.13239","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T15:47:45Z","timestamp":1743349665000},"page":"530-536","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Events in Hemodialysis Patients With Venous Catheters Locked With 30% Trisodium Citrate Versus Alternative Locking Solutions"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4655-6707","authenticated-orcid":false,"given":"George","family":"Miller","sequence":"first","affiliation":[{"name":"Medical Components Inc., Clinical Affairs  Harleysville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Feuersenger","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Deutschland GmbH  Bad Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Ogujiofor","sequence":"additional","affiliation":[{"name":"Medical Components Inc., Clinical Affairs  Harleysville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Juergens","family":"Arens","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Deutschland GmbH  Bad Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Blanco","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Deutschland GmbH  Bad Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rukhaiya","family":"Fatima","sequence":"additional","affiliation":[{"name":"Medical Components Inc., Clinical Affairs  Harleysville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Medical Components Inc., Clinical Affairs  Harleysville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Zabaleta","sequence":"additional","affiliation":[{"name":"Medical Components Inc., Clinical Affairs  Harleysville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.001"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328365ba53"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2118068"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-016-0929-4"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp651"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12492"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2012.00691.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004100870"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.01.259"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn299"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2320-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0101-28002011000100012"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl606"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl570"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120300"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21346"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.2000.4.1.22"},{"key":"e_1_2_9_19_1","unstructured":"Food US Adminstration D \u201cFDA Issues Warning on Tricitrasol Dialysis Catheter Anticoagulant \u201dFDA Talk Pap T100 16."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP69317"},{"key":"e_1_2_9_21_1","unstructured":"P.Theophrastus \u201cThe Dose Make the Poison Theophrastus Paracelsus: Works \u201d(Darmstadt: 1965) 508\u2013513."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-019-0553-4"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000274461"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.7.1521-a"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112230"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-449"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30046-2"},{"key":"e_1_2_9_28_1","first-page":"11985","article-title":"Anticoagulant Therapies Versus Heparin for the Prevention of Hemodialysis Catheter\u2010Related Complications: Systematic Review and Meta\u2010Analysis of Prospective Randomized Controlled Trials","volume":"8","author":"Liu J.","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00657-7"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc3824"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0773-5"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-2-10"},{"issue":"4","key":"e_1_2_9_33_1","first-page":"S94","article-title":"EuCliD (European Clinical Database): A Database Comparing Different Realities","volume":"14","author":"Marcelli D.","year":"2001","journal-title":"Journal of Nephrology"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.13239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hdi.13239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.13239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:30:59Z","timestamp":1773192659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.13239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/hdi.13239"],"URL":"https:\/\/doi.org\/10.1111\/hdi.13239","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2024-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}